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P2X receptors (P2XR) act as ligand-gated, cation-selective ion channels. A common characteristic of all seven P2X family members is a
conserved consensus sequence for protein kinase C (PKC)-mediated phosphorylation in the intracellular N-terminus of the receptor. Activation of
PKC has been shown to enhance currents through P2X3R, however the molecular mechanism of this potentiation has not been elucidated. In the
present study we show that activation of PKC can enhance adenosine triphosphate (ATP)-mediated Ca2+ signals ∼2.5-fold in a DT-40 3KO cell
culture system (P2 receptor null) transiently overexpressing P2X3R. ATP-activated cation currents were also directly studied using whole cell
patch clamp techniques in HEK-293 cells, a null background for ionotropic P2XR. PKC activation resulted in a ∼8.5-fold enhancement of ATP-
activated current in HEK-293 cells transfected with P2X3R cDNA, but had no effect on currents through either P2X4R- or P2X7R-transfected
cells. P2X3R-transfected HEK-293 cells were metabolically labeled with
32PO4
− and following treatment with phorbol-12-myristate-13-acetate
(PMA) and subsequent immunoprecipitation, there was no incorporation of 32PO4
− in bands corresponding to P2X3R. Similarly, in vitro
phosphorylation experiments, utilizing purified PKC catalytic subunits failed to establish phosphorylation of either P2X3R or P2X3R-EGFP. These
data indicate that PKC activation can enhance both the Ca2+ signal as well as the cation current through P2X3R, however it appears that the
regulation is unlikely to be a result of direct phosphorylation of the receptor.
© 2006 Elsevier B.V. All rights reserved.Keywords: Protein kinase C; Phosphorylation; Calcium signaling; P2X; Purinergic receptor; P2X3R1. Introduction
Extracellular ATP can initiate signal transduction by
activating purinergic receptors of the P2X and P2Y subtypes.
P2XR are ligand-gated, cation selective ion channels; whereas
P2Y receptors (P2YR) are G-protein coupled receptors
(GPCR). Seven genes have been identified as coding for
P2XR (P2X1–P2X7R) [1]. The functional channel is formed by
three P2X subunits [2]. Each subunit contains two transmem-
brane spanning domains, with both the N- and C-termini facing
the cytoplasm, and the large extracellular loop containing the
ATP binding site [1].
The N- and C-termini of P2XR provide putative unique areas
of regulation/modulation by intracellular factors. One con-
served feature of all members of the P2XR family is a consensus⁎ Corresponding author. Tel.: +1 585 275 6128; fax: +1 585 273 2652.
E-mail address: David_Yule@urmc.rochester.edu (D.I. Yule).
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doi:10.1016/j.bbamcr.2006.09.020sequence for PKC mediated phosphorylation in the N-terminal
domain. This region consists of the amino acids Thr-X-Arg/Lys,
or T-X-R/K (X=amino acid). The importance of this site in the
N-terminus of P2X2R was first implicated by studies showing
that the fast-desensitizing kinetics of a C-terminal truncated
receptor could be transformed into one with slow-desensitizing
kinetics following treatment with PKC activators [3]. This study
also showed that mutations in the PKC consensus sequence
exhibited rapid desensitization kinetics and that residue Thr18
was phosphorylated in wild-type P2X2R [3].
Expression of P2X3R were first described in sensory neurons
[4,5]. Inflammatory mediators, including the phospholipase C
coupled ligands, substance P and bradykinin together with
phorbol ester treatment to directly activate PKC have also been
shown to augment P2X3R currents [6]. However, this particular
study was unable to determine whether PKC-mediated
phosphorylation occurred directly, presumably at the N-
terminal PKC site, or alternatively that the effect was mediated
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fact, recent studies have even suggested the possibility of an
external PKC site on the receptor [7,8]. Therefore the goal of
this study was to determine specifically whether P2X3R are
directly phosphorylated by PKC.
2. Materials and methods
2.1. Digital imaging of intracellular Ca2+
DT-40 3KO cells were used as a null background for P2XR [9]. These cells
lack all three (3KO) inositol 1,4,5-trisphosphate receptors (InsP3R) thus
avoiding any possible Ca2+ response as a consequence of P2YR activation.
DT-40 3KO cells were kindly provided by Dr. Kurosaki (Kansai Medical
University, Japan) [10] and maintained as previously described [11–14]. DT-40
3KO cells provided a convenient system for digital Ca2+ imaging studies since
multiple cells from a single experimental run could be averaged. HEK-293 cells
could not be used for Ca2+ imaging studies since they express endogenous P2YR
that are activated by extracellular ATP [15]. DT-40 3KO cells were loaded with
the Ca2+ sensitive dye Fura-2 AM (2 μM, TEFLABS, Austin, TX) by incubation
for 15 min at room temperature (RT). Subsequently, cells were removed from the
Fura-2 AM containing solution, and resuspended in a physiological saline
solution used for imaging experiments that contained (mM): 137 NaCl, 0.56
MgCl2, 4.7 KCl, 1 Na2HPO4, 10 HEPES, 5.5 glucose, 1.26 CaCl2, pH 7.4.
Rapid solution changes were performed utilizing an electronic solenoid
controlled perfusion system and gravity fed reservoirs (Warner Instruments,
Hamden, CT). Imaging was performed using an inverted epifluorescence Nikon
microscope with a 40× oil immersion objective lens (numerical aperture, 1.3).
Fura-2 loaded cells were excited alternately with light at 340 and 380 nm using a
monochrometer-based illumination system and the emission at 510 nm captured
using a high speed, digital CCD camera (TILL Photonics, Pleasanton, CA). The
fluorescent ratio of 340 nm/380 nm was calculated and all data is presented as
the change in ratio units. Images were acquired at a rate of 1 Hz with an exposure
of 20 ms. All imaging experiments were performed at RT, essentially as
previously described [16,17]. Traces are from a single cell, representative of
multiple individual cells in a particular experimental run and n represents the
number of experimental runs, with at least 3 cells per experimental run.
2.2. Transfection of DT-40 3KO cells
Human P2X3R cDNA, kindly provided by R.A. North (University of
Manchester, UK), was transiently transfected into DT-40 3KO cells using a
Nucleofector System (Amaxa, Gaithersburg, MD) following the instructions
provided. Specifically, 5×106 cells were resuspended in 100 μL of Cell-line
Nucleofector Kit T solution and were co-transfected with 5 μg of the P2X3R
cDNA and 1 μg of pHcRed 1-N1 cDNA (red fluorescent protein for visualization
of positively transfected cells) using Nucleofector program B-23. Immediately
after transfection, 500 μL of media was added to the Nucleofector cuvette,
followed by transfer of the cells to a single well of a 6 well culture plate which
contained 1.5 mL of media. Experiments were performed 24 h after transfection.
2.3. Creation of P2X3R-EGFP construct
Human P2X3R cDNA was amplified by PCR. HindIII and SalI restriction
sites were incorporated into the oligonucleotides used for PCR amplification.
The PCR products were restriction enzyme-digested and ligated into pEGFP-N3
at the HindIII and SalI sites (BD Biosciences Clontech, San Jose, CA). This
construct was verified by sequencing and creates a fusion protein with EGFP at
the C-terminus of the human P2X3R.
2.4. Transfection of HEK-293 cells
Human P2X3R, human P2X3R-EGFP, rat P2X4R, rat P2X7R (rat P2XR
cDNA also kindly provided by R.A. North), human 3HA-M3R (obtained from
the UMR cDNA resource center, available on the World Wide Web at www.
cdna.org), or rat S1−/S2+ InsP3R type I cDNA (kindly provided by Dr. S. Joseph,Thomas Jefferson University) was transiently transfected into HEK-293 cells
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) following the instructions
provided. Specifically, 5×104 cells were grown on 25 mm cover slips in 6 well
culture plates and were co-transfected with 1 μg of the P2XR cDNA and 100 ng
of pHcRed 1-N1 cDNA as described previously [17].
2.5. Whole cell patch clamp recordings
ATP-activated cation currentswere recorded at a sampling rate of 1 kHz using
an Axopatch 200A patch clamp amplifier (Axon Instruments, Union City, CA),
Axon digital interface, and pCLAMPversion 9.0 software under whole cell patch
clamp conditions. To measure ATP-activated currents in HEK-293 cells, cells
were perfused with an extracellular solution containing (mM): 140 NaCl, 5 CsCl,
1.2 MgCl2, 1 CaCl2, 10 HEPES–CsOH, 10 D-glucose, pH 7.4. Internal patch
solution contained (mM): 140 Cs-acetate, 1.22 MgCl2, 10 HEPES–CsOH, 0.1
EGTA, 10 NaCl, 0.0365 CaCl2, pH 7.2. Intervals of 2–3 min were allowed
between patch rupture and stimuli to allow for equilibrationwith the patch pipette
solution. HEK-293 cells were held at a holding potential of−30mV. Experiments
were performed at RT.
2.6. Immunoprecipitation, electrophoresis and immunoblotting
Immunoprecipitated samples were prepared from either mock-, InsP3R
type I-, 3HA-M3R-, P2X3R-, or P2X3R-EGFP-transfected HEK-293 cells. The
media was removed and cells were washed in ice-cold PBS, followed by
resuspension in 400 μL of ice-cold RIPA (RadioImmunoPrecipitation Assay)
lysis buffer that contained (mM): 50 NaF, 2 EDTA, 150 NaCl, 0.01 Na-
Phosphate, 1% nonidet P-40 (NP-40), 1% Na-deoxycholate, 0.1% SDS, and 1
Complete EDTA-free protease inhibitor mixture tablet (Roche, Mannheim,
Germany). Samples were left on ice with gentle agitation for 30 min to
solubilize. Immunoprecipitating primary antibodies, polyclonal α-P2X3R from
Alomone Labs (Jerusalem, Israel), polyclonal α-InsP3R type I from
Calbiochem (San Diego, CA), monoclonal α-GFP from Roche (Mannheim,
Germany), and monoclonal α-HA.11 from Covance (Princeton, NJ) were used
at a 1:100 dilution and incubated for 2 h at 4 °C with rotation. Protein A or G
sepharose (70 μL or 50 μL) was added to each sample and rotated at 4 °C for
1 h, then washed and centrifuged seven times, before final resuspension in 1×
SDS loading buffer. Samples were resolved on 7.5% SDS-PAGE and
transferred as described previously [17]. Polyclonal α-P2X3R (1:200 dilution)
and α-InsP3R type I (1:750 dilution) primary antibodies (see above) were used
following the manufacturer's instructions for immunoblotting. Monoclonal α-
GFP (1:3000 dilution) and α-HA.11 (1:1000 dilution) primary antibodies (see
above) were used following the manufacturer's instructions for immunoblot-
ting. Proteins were visualized as previously described [17].
2.7. Metabolic labeling of HEK-293 cells
Mock-, InsP3R type I-, or P2X3R-transfected HEK-293 cells were
metabolically labeled by incubating for 3 h with 150 μCi/mL 32PO4-
(PerkinElmer, Boston, MA) in a phosphate-free DMEM (Invitrogen, Carlsbad,
CA). Following incubation, cells were treated with or without 100 nM PMA for
10 min at RT. Cells were washed once in an ice cold TBS solution that contained
(mM): 20 Tris, 138 NaCl, pH 7.6. Cells were then resuspended in 400 μL of ice-
cold RIPA lysis buffer and immunoprecipitations were performed as mentioned
above. Samples were resolved on 7.5% SDS-PAGE and then the gel was placed
on a gel dryer for 1 h at 80 °C (Bio-Rad, Hercules, CA). The dried gel was then
placed in a 20×25 cm phosphor screen (Amersham Biosciences, Piscataway,
NJ) for 22–72 h before visualizing using a Molecular Dynamics Phosphor-
Imager. Dried gels were then rehydrated for 30 min in SDS-PAGE running
buffer that contained (mM): 25 mM Tris, 192 Glycine, 0.1% SDS, pH 8.3.
Rehydrated gels were transferred to nitrocellulose and proteins were visualized
as previously described in the immunoblotting section.
2.8. In vitro PKC phosphorylation assay
P2X3R, P2X3R-EGFP, 3HA-M3R, or InsP3R type I were immunoprecipi-
tated (see above protocol) from mock-, P2X3R-, P2X3R-EGFP-, 3HA-M3R-, or
168 D.A. Brown, D.I. Yule / Biochimica et Biophysica Acta 1773 (2007) 166–175InsP3R type I transiently transfected HEK-293 cells and transferred from ice
cold RIPA lysis buffer after three washes to PKC phosphorylation buffer
containing 20 mM Tris–HCl, 10 mM MgCl2, and Complete, EDTA-free
protease inhibitor cocktail tablets (Roche, Mannheim, Germany), pH 7.5.
Samples were briefly centrifuged and washed three times at 4 °C in PKC
phosphorylation buffer. After the final wash, all remaining buffer was removed
and samples were then resuspended in PKC phosphorylation buffer containing
20 μM ATP, 8 μL of [γ-32P]-ATP (40 μCi) (PerkinElmer, Boston, MA), and
either 10 ng of a catalytically active PKC fragment from rat brain (Calbiochem,
San Diego, CA), which does not require Ca2+ or phosphatidylserine for its
activity [18], were added or omitted as indicated (+ or − PKC). Final volume
was 400 μL. Samples were mixed gently and incubated at 30 °C for 15 min.
Reactions were quenched by adding 1.3 mL of ice-cold PKC phosphorylation
buffer containing 1 mM ATP. Samples were briefly centrifuged at 4 °C and
washed twice with 1.5 mL of phosphorylation buffer containing 1 mM ATP,
finally resuspended in 1X SDS loading buffer. Samples were resolved on 7.5%
SDS-PAGE and then the gel was dried. The dried gel was then placed in a
20×25 cm phosphor screen (Amersham Biosciences, Piscataway, NJ) for 60 h
before visualizing using a Molecular Dynamics PhosphorImager. Dried gels
were then rehydrated and proteins were visualized as described above.
2.9. Statistical analysis
Statistical significance was determined using either a paired or unpaired
t test as indicated. Data from several cells in a particular experimental run were
averaged, and experimental averages were used to calculate the mean±S.E.
Two-tailed p values of less than 0.05 were considered statistically significant.Fig. 1. PMA-induced potentiation of ATP-activated P2X3R-mediated Ca
2+
signals in DT-40 3KO cells. (A) Mock-transfected DT-40 3KO cells do not
respond to 200 μM ATP in the absence or following 100 nM PMA treatment.
Cells were confirmed to be responsive since 30 μM CPA caused Ca2+ release
from intracellular stores. (B) P2X3R-transfected DT-40 3KO cells elicit a small,
reproducible Ca2+ response upon 200 μM ATP stimulation. (C) Treatment with
100 nM PMA of P2X3R-transfected DT-40 3KO cells resulted in a ∼2.5-fold
enhanced Ca2+ signal. Note CPA treatment resulted in a Ca2+ response in P2X3R-
transfected DT-40 3KO cells similar to mock-transfected cells. (D) Data from
paired experiments, where the maximum Ca2+ response over baseline of the
second application of ATP was normalized relative to the first application of ATP
either in the presence or absence of PMA. The data are presented as the mean±
S.E. (*p<0.05). Each trace is representative of three or more experiments.3. Results
3.1. Effects of PKC activation on ATP-evoked Ca2+ signals in
DT-40 3KO cells
DT-40 3KO cells are a useful screening tool for P2XR studies
since activity from multiple cells can be recorded in a single
experimental run and unlike most cells lines, including HEK-
293 cells, they have no endogenous P2YR [9]. To verify that DT-
40 3KO cells represent a null background for P2R, Ca2+
signaling events were first evaluated in mock-transfected DT-40
3KO cells following ATP stimulation [9]. No Ca2+ signals were
evoked by 200–500 μM ATP or 100 nM PMA in mock-
transfected cells (Fig. 1A). However, cyclo-piazonic acid (CPA)
treatment, to inhibit the sarco-endoplasmic reticulum Ca2+-
ATPase (SERCA) and promote Ca2+ leak from intracellular
stores, confirmed the viability of the measurement (Fig. 1A). In
P2X3R-transfected DT-40 3KO cells, stimulation with 200 μM
ATP caused a small reproducible Ca2+ transient (Fig. 1B, P2X3R
control; second response 85±16% of initial stimulation, n=6).
Importantly, after treatment of P2X3R-expressing cells with
100 nM PMA for 4–5 min, subsequent reapplication of 200 μM
ATP caused a significant ∼ 2.5-fold enhancement of the Ca2+
signal over control values (Fig. 1C, P2X3R PMA treatment;
second response 268±42% of initial stimulation, n=12,
p=0.008). Note treatment with CPA resulted in a similar Ca2+
response in either mock- or P2X3R-transfected DT-40 3KO
cells. When desensitization of the second ATP-induced Ca2+
signal in the absence of PMAwas considered, this potentiation
reached ∼3.2-fold (Control; second response 85±16% of initial
stimulation versus PMA treatment; second response 268±42%
of initial stimulation). These data are summarized in Fig. 1D.3.2. PMA significantly enhances P2X3R current
Quantifying the magnitude of the PMA-induced enhance-
ment on P2X3R-mediated Ca
2+ signaling was complicated by
the initial small responses observed in DT-40 3KO cells. One
possible reason for the small Ca2+ response is that these indirect
measurements of channel activity rely on a spatially averaged
global signal from the Ca2+ indicator, which might under-
estimate the signal if locally defined. In addition, the fact that
the receptor desensitizes very rapidly may compound this
problem. As a direct measurement of channel activity, we
therefore used an electrophysiological approach to study the
regulation of P2X3R in isolation following expression in P2XR-
null HEK-293 cells [1,19–24].
Fig. 2 shows membrane currents recorded in the whole cell
configuration of the patch clamp technique in response to
extracellular ATP stimulated at a holding potential of −30 mV.
The pipette solution and holding potential were chosen to isolate
inwardly directed cation currents, predominately carried by Na+,
as we have reported previously [17]. No inward currents were
Fig. 2. PKC activation enhances ATP-activated current through P2X3R in HEK-
293 cells. Mock- or P2X3R-transfected HEK-293 cells were whole cell patch
clamped at a holding potential of −30 mV. (A) Mock-transfected HEK-293 cells
did not elicit any current upon ATP stimulation. (B) P2X3R-transfected HEK-
293 cells elicit current when treated with 1 μM ATP. (C) PMA treatment of
P2X3R-transfected HEK-293 cells resulted in a ∼8.5-fold enhanced inward
current when cells were re-exposed to ATP (control 72±7% of initial response
versus PMA 857±199% of initial response, n=3 and n=6, respectively,
p=0.03). (D) Whole cell patch clamp data from paired experiments, where the
baseline subtracted maximum inward current of the second application of ATP
was normalized relative to the first application of ATP either in the presence or
absence of PMA. The data are presented as the mean±S.E. (*p<0.05). Each
trace is representative of three or more experiments.
Table 1
N-terminus alignment of P2XR amino acid sequences
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Stimulation of P2X3R-transfected cells with 1 μMATP resulted
in an inward current, repeated stimulation after 4–5min revealed
a measurable desensitization of the P2X3R activity (Fig. 2B,
P2X3R control; second response 72±7% of initial stimulation,
n=3). In spite of this desensitization, treatment with PMA
(4 min) in P2X3R expressing cells significantly enhanced the
maximum amplitude of the inward current ∼8.5-fold (Fig. 2C,
P2X3R PMA treatment; second response 857±199% of initial
stimulation, n=6, p=0.03). When desensitization of the second
ATP response in the absence of PMA was considered, thispotentiation reached almost 12-fold (Control; second response
72±7% of initial stimulation versus PMA treatment; second
response 857±199% of initial stimulation). These data are
summarized in Fig. 2D.
3.3. PMA has no effect on P2X4R or P2X7R current
One possible mechanism underlying this observation is a
phosphorylation event occurring on the PKC consensus site in
the N-terminal domain, conserved among all P2XR family
members. Table 1 shows the amino acid alignment of the N-
terminal regions of all seven rat P2XR [1]. It should be noted
that human P2X3R is identical to rat P2X3R in this region. The
underlined residues represent the PKC consensus site, where the
highlighted Thr (T) is presumably the putative phosphorylation
site [1]. Given the similarities in this region among P2XR, we
next determined if treatment with PMA would also enhance
signaling through both P2X4R and P2X7R.
Stimulation of P2X4R-transfected HEK-293 cells with
25 μM ATP elicited a robust inward current, which was
unaffected by PMA treatment (Fig. 3A, P2X4R PMA treatment;
second response 74±2% of initial stimulation, n=4). Stimula-
tion of P2X7R-transfected HEK-293 cells with 100 μM ATP
evoked inward currents of similar magnitude to those stimulated
by 25 μMATP in P2X4R-transfected HEK-293, consistent with
reported EC50 values for each receptor (Fig. 3B) [25]. Similarly,
PMA treatment did not significantly enhance the current (Fig.
3B, P2X7R PMA treatment; second response 72±7% of initial
stimulation, n=10). Currents through both P2X4R and P2X7R
in the presence of PMA were similar to control values that we
have previously reported under identical conditions [17]. These
data are summarized in Fig. 3C.
3.4. Mechanism of PMA enhancing P2X3R channel activity
Our results have shown that following PKC activation,
P2X3R channel activity is significantly augmented in two
different cell lines following transient expression of the
receptor. The simplest explanation of the underlying mechanism
for this enhancement would be a PKC-mediated phosphoryla-
tion event occurring at the N-terminal region of the receptor.
Contrary to this idea, it should be noted that PMA treatment can
enhance P2X3R, but not P2X4R or P2X7R inward currents, yet
all three receptors share a similar N-terminal PKC phosphor-
ylation site. These findings might suggest that the conserved N-
terminal PKC site might not be a universal substrate for
phosphorylation/regulation by PKC. To determine if receptor
Fig. 3. PKC activation does not enhance ATP-activated current through either P2X4R or P2X7R in HEK-293 cells. P2X4R- or P2X7R-transfected HEK-293 cells were
whole cell patch clamped at a holding potential of −30 mV. (A) Treatment of P2X4R-transfected HEK-293 cells with 25 μMATP resulted in an inward current, which
was not enhanced by PMA treatment. (B) Treatment of P2X7R-transfected HEK-293 with 100 μM ATP also resulted in an inward current, however again PMA
treatment did not enhance the inward current. (C) Whole cell patch clamp data from paired experiments, where the baseline subtracted maximum inward current of the
second application of ATP in the presence of PMAwas normalized relative to the first application of ATP in the absence of PMA. PMA did not enhance the inward
current in HEK-293 cells transiently expressing either P2X4R or P2X7R (P2X4R, PMA 74±2% of initial response; P2X7R, PMA 72±7% of initial response, n=4 and
n=10, respectively). The data are presented as the mean±S.E. (*p<0.05). Each trace is representative of three or more experiments.
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performed both intact cell and in vitro phosphorylation
experiments after immunoprecipitation with a P2X3R antibody.
Immunoprecipitation followed by immunoblotting with a
P2X3R antibody was performed to verify purification of the
receptor. In lysates from P2X3R-transfected HEK-293 cells, a
single major band was identified by a P2X3R-specific antibody,
which was absent in mock-transfected cells (Fig. 4A). The size
of the immunoreactive band was larger than the predicted size
(44 kDa in human), as reported previously [26,27]. Where
indicated, the lower band marked (*) near the 50 kDa marker in
samples depicts the band corresponding to the heavy chain of
the antibody used for immunoprecipitation.
As a positive control for PKC-mediated phosphorylation,
immunoprecipitation followed by immunoblotting with a
InsP3R type I antibody was also performed. This control
was chosen because this ligand-gated ion channel is also
involved in Ca2+ signaling and has been shown to be asubstrate for PKC [28,29]. Lysates from InsP3R type I-
transfected HEK-293 cells revealed a single distinct band of
the predicted size (313 kDa), which was not evident in mock-
transfected cells (Fig. 4B).
To determine if activation of endogenous PKC results in
P2X3R phosphorylation, we first metabolically labeled mock-,
InsP3R type I-, or P2X3R-transfected cells with
32PO4
−.
Subsequently, protein that had incorporated 32PO4
− was detected
by autoradiography. Following treatment with PMA and
immunoprecipitation with either InsP3R type I or P2X3R
antibodies, there was an enhanced labeling of a single band in
InsP3R type I-transfected samples compared to control
(Fig. 5A). This demonstrates that InsP3R (type I) are directly
phosphorylated, presumably by a PKC-mediated process. In
contrast, under identical conditions, no detectable signal was
observed at the appropriate molecular weight for P2X3R
(Fig. 5C). All mock-, InsP3R type I-, or P2X3R-transfected
samples shown were run on the same gel, thus we next
Fig. 4. Immunoprecipitation and immunoblotting using receptor specific
antibodies for P2X3R and InsP3R type I. Mock-, InsP3R type 1-, or P2X3R-
transfected HEK-293 cells were utilized for immunoprecipitation experiments.
(A) A commercially available P2X3R-specific antibody was used for both
immunoprecipitation and immunoblotting, which recognizes a single distinct
band in P2X3R-transfected HEK-293 cells, however, no band was detected in
mock-transfected cells. The lower band located near the 50 kDa marker in both
samples is the heavy chain from the antibody used for immunoprecipitation
(note *), which was not present in control experiments where the antibody used
for immunoprecipitation was absent (data not shown). (B) A commercially
available InsP3R type I antibody was used for both immunoprecipitation and
immunoblotting, which recognizes a single distinct band in InsP3R type I-trans-
fected HEK-293 cells, however, no band was detected in mock-transfected cells.
Fig. 5. PMA treatment phosphorylates InsP3R type I, but does not phosphorylate P2X
were metabolically labeled with 32PO4
− and incubated with (+) or without (−) 100 nM
increase in 32P incorporationwas observed in InsP3R type 1-expressing cells after PMA
of rehydrated gel shown in Panel A, using a InsP3R type I antibody, confirms similar e
was no 32P incorporation observed in either mock- or P2X3R-transfected lanes treated w
C, using a P2X3R antibody, confirming immunoprecipitation of the P2X3R (see arrow)
cells (*Indicates heavy chain). All blots were repeated with similar results.
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gel, transferring to nitrocellulose, and immunoblotting with
either InsP3R type I or P2X3R antibodies. Immunoblotting with
a InsP3R type I antibody showed that both InsP3R type I-
transfected samples contained similar amounts of protein and
confirmed the identity based on the size of the phosphorylated
protein detected in Fig. 5A (Fig. 5B). Immunoblotting with a
P2X3R antibody demonstrated similar expression of P2X3R in
P2X3R-transfected samples, that was absent in mock-transfected
samples (Fig. 5D). These data confirm that the P2X3R was
present in Fig. 5C. It is formally possible, however, that low level
phosphorylation of the P2X3R might be below the sensitivity of
this detection system. In addition, it is possible that 100 nM
PMA stimulation is not sufficient to promote phosphorylation of
the receptor, even though functional effects are readily evident.
To address these issues, we next attempted to directly
phosphorylate the P2X3R directly using active catalytic PKC
subunits in vitro.
To determine whether the P2X3R can be directly phos-
phorylated by PKC, the receptor was purified by immunopre-
cipitation, followed by treatment with a catalytically active
PKC fragment from rat brain and [γ-32P]-ATP in vitro. This
PKC fragment has been shown previously to phosphorylate
PKC substrates such as the δ2 glutamate receptor [30]. Again,
as a positive control, InsP3R type I-transfected HEK-293 cells
were included. After a 15 min incubation there was no
detectable incorporation of 32P in either mock or P2X3R3R in intact cells. Mock-, InsP3R type 1-, or P2X3R-transfected HEK-293 cells
PMA for 10 min and then utilized for immunoprecipitation experiments. (A) An
treatment (Lane 2, +) compared to control treatment (Lane 1,−). (B) Immunoblot
xpression levels in both samples and confirms protein size (see arrow). (C) There
ith PMA compared to control. (D) Immunoblot of rehydrated gel shown in Panel
from P2X3R transfected HEK-293 cells, that was not present inmock-transfected
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markers, even after substantial overexposure (Fig. 6A).
Following rehydration and transferring this gel to nitrocellu-
lose, immunoblotting with a P2X3R antibody confirmed the
presence of the P2X3R protein in P2X3R- but not mock-
transfected cells (Fig. 6B, bottom). InsP3R type I-transfected
cells showed an increase in 32P incorporation after 15 min of
PKC and [γ-32P]-ATP treatment at the correct molecular weight
of the receptor. The presence of the InsP3R type I was
confirmed after rehydrating the gel, transferring to nitrocellu-
lose, and immunoblotting these samples with a InsP3R type I
antibody (Fig. 6B, top). This increase in 32P incorporation was
not present in the lane lacking PKC addition. These results
demonstrate that P2X3R do not appear to be a substrate for
PKC-mediated phosphorylation.
A possibility exists that the P2X3R was not being efficiently
immunoprecipitated from our samples, since immunoblotting
for P2X3R only resulted in a modest signal. To address this
issue we generated a C-terminal EGFP tagged human P2X3R.
This construct was confirmed to be functional by electro-
physiological recordings and retained enhancement by PMA
treatment (data not shown). Epitope tagging this receptor with
EGFP has two distinct advantages; it allows for better resolution
from the heavy chain of the antibody used for immunopreci-
pitation. Secondly, it also allows us to utilize an α-GFP
antibody for a more efficient immunoprecipitation. To deter-
mine whether the P2X3R-EGFP can be directly phosphorylated
by PKC, the receptor was purified by immunoprecipitation,
followed by treatment with a catalytically active PKC fragment
from rat brain and [γ-32P]-ATP in vitro. In addition, InsP3R type
I- and 3X HA-tagged human M3R- (3HA-M3R) transfected
HEK-293 cells were included as positive controls. Human M3R
has been utilized previously as a positive control for P2X1R
phosphorylation [31], and it is similar in size to P2X3R-EGFP.Fig. 6. PKC activation phosphorylates InsP3R type I in vitro, but does not phosphory
utilized for immunoprecipitation experiments. (A) Immunoprecipitated samples were i
presence of [γ-32P]-ATP in vitro. 32P incorporation was observed in InsP3R type 1-ex
32P incorporation in the region of the P2X3R for either mock- or P2X3R-transfected HE
rehydrated gel shown in Panel A, using a InsP3R type I antibody (top), or a P2X3R a
P2X3R-transfected samples and confirms protein size (see arrows, *Indicates heavyAfter a 15 min incubation there was no detectable incorporation
of 32P in either mock or P2X3R-EGFP immunoprecipitated
samples between the 75 and 100 kDa markers, even after
substantial overexposure (Figs. 7A and B). Following rehydra-
tion and transferring this gel to nitrocellulose, immunoblotting
with an α-GFP antibody confirmed the presence of the P2X3R-
EGFP protein in P2X3R-EGFP- but not mock-transfected cells
(Fig. 7C, right). 3HA-M3R- and InsP3R type I-transfected cells
showed an increase in 32P incorporation after 15 min of PKC
and [γ-32P]-ATP treatment at the correct molecular weight of
each receptor (Figs. 7A and B). The human M3 receptor has
been shown previously to migrate as a diffuse band running at
approximately 97–110 kDa due to post-translational modifica-
tion of the receptor [32]. The presence of both receptors was
confirmed after rehydrating the gel, transferring to nitrocellu-
lose, and immunoblotting these samples with either an α-HA or
α-InsP3R type I antibody (Fig. 7C, left and center). This
increase in 32P incorporation was not present in the lanes
lacking PKC treatment. These results demonstrate that P2X3R-
EGFP do not appear to be a substrate for PKC-mediated
phosphorylation. This additional information reinforces the
notion that the regulation of P2X3R by PKC is likely indirect
and thus presumably involves the phosphorylation of an
unknown accessory protein.
4. Discussion
The present study demonstrates that PKC activation can
significantly enhance both the Ca2+ signal as well as the cation
current through P2X3R in different cell lines. More importantly,
this is the first study that has specifically addressed whether the
P2X3R is directly phosphorylated after PKC activation.
Utilizing two different techniques, activation of PKC failed to
increase the phosphorylation of the P2X3R.late P2X3R. Mock-, InsP3R type 1-, or P2X3R-transfected HEK-293 cells were
ncubatedwith (+) or without (−) purified PKC catalytic subunits for 15 min in the
pressing cells when PKC was present (Lane 2), however, there was no detectable
K-293 cells when PKCwas present (Lane 4 and Lane 6). (B) Immunoblots of the
ntibody (bottom), confirms similar expression levels in both InsP3R type I- and
chain). All blots were repeated with similar results.
Fig. 7. PKC activation phosphorylates InsP3R type I and 3HA-M3R in vitro, but does not phosphorylate P2X3R-EGFP. Mock-, InsP3R type 1-, 3HA-M3R-, P2X3R-
EGFP-transfected HEK-293 cells were utilized for immunoprecipitation experiments. (A) Immunoprecipitated samples were incubated with (+) or without (−) purified
PKC catalytic subunits for 15 min in the presence of [γ-32P]-ATP in vitro. 32P incorporation was observed in 3HA-M3R- and InsP3R type 1-expressing cells when PKC
was present (Lanes 2 and 4), however, there was no detectable 32P incorporation in the region of the P2X3R-EGFP for either mock- or P2X3R-EGFP-transfected HEK-
293 cells when PKC was present (Lane 6 and Lane 8) even after a longer exposure (B). (C) Immunoblots of the rehydrated gel shown in (A and B), using a HA
antibody (left), a InsP3R type I antibody (center), or a GFP antibody (right), confirms similar expression levels in 3HA-M3R-, InsP3R type I-, and P2X3R-EGFP-
transfected samples and confirms protein size (see arrows). All blots were repeated with similar results.
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of P2XR by PKC. It was first reported that phorbol ester treatment
caused a mutant P2X2Rwith truncated C-terminus to convert from
one exhibiting rapid desensitizing currents to slow desensitizing
currents [3]. In addition, P2X2R were shown to be phosphorylated
at Thr18 using an antibody that recognizes a phosphothreonine–
proline motif, whereas the P2X2R mutant K20T was not
recognized [3]. These authors showed that P2X2R are constitu-
tively phosphorylated, thus giving these receptors their character-
istic slow rate of desensitization; however they did not demonstrate
whether the truncated C-terminus mutant P2X2R was phosphory-
lated at this N-terminal site following phorbol ester treatment. It
should be noted that the particular antibody used to detect PKC-
mediated phosphorylation would not be of use in the present study
because it specifically recognizes a motif absent in P2X3R.
Ennion and Evans demonstrated that disruption of the N-
terminal PKC site in P2X1R (T18A) caused reduced peak
current amplitude as well as rapid desensitization kinetics [33].
The authors speculated that PKC-mediated phosphorylation/
dephosphorylation of P2X1R was a mechanism for regulating
channel function [33]. In a further study, the P2X1R mutants
T18A, T18N, P19V, and R20Twere made and the authors found
that all mutations except P19V significantly reduced the current
[34]. They also indicated that the wild-type P2X1R was
phosphorylated, whereas the mutant R20T was not, after
immunoblotting with an antibody that recognizes a phospho-
threonine–proline motif [34]. However, Evans and colleagues
later showed that activation of PKC, mediated either by GPCR
stimulation (metabotrophic glutamate receptor 1α, P2Y1R, or
P2Y2R) or PMA, still enhanced current through point mutants
with the N-terminal PKC site disrupted (R20I, R20A, and
T18V). These data suggested PKC activation does not involve
P2X1R phosphorylation in this region [31]. This prediction was
confirmed after radiolabeling phosphorylated proteins in the
presence or absence of PMA, where P2X1R were basallyphosphorylated and no enhanced phosphorylation was observed
after PMA treatment. These data in total suggest that the
mechanism of PKC-mediated P2X1R regulation likely involves
the phosphorylation of an accessory protein [31].
P2X3R had been shown to be positively enhanced by Gq-
coupled inflammatory mediators such as substance P and
bradykinin. These effects could be mimicked by phorbol ester
treatment and blocked by inhibitors of protein kinases [6].
The most plausible explanation for this enhancement was
either an N-terminal PKC-mediated phosphorylation or an
unidentified protein that was phosphorylated and controls
activity of P2X receptors [6]. However, there have been
recent reports that P2X3R are regulated by ecto-PKC activity
[7]. P2X3R have seven PKC consensus sequences, including
the conserved N-terminal intracellular PKC site as well as a
C-terminal intracellular PKC site. Mutation of the C-terminal
intracellular PKC site did not inhibit PKC-mediated P2X3R
potentiation [6]. However, P2X3R also have five external
PKC consensus sequences. The authors argued that since
PKC activators such as PMA and DAG-lactone can transverse
the cell membrane, that it gives no specificity as to the
intracellular or extracellular location of the phosphorylation
site. External PKC site mutants T134A and S178A both
abolished the UTP-induced potentiation of the current through
P2X3R, yet mutants T196A and S269A had no effect [7].
Interestingly, activity of the internal PKC site mutant T13A,
was not enhanced by UTP in this study, although a previous
report has shown that this same mutation, P2X3T13A was still
enhanced by PKC activation [6]. The substitution of the same
four external PKC sites to the negatively charged Asp residue
(T134D, S178D, T196D, and S269D), to mimic phosphoryla-
tion, all prevented the potentiation by UTP [8]. To
summarize, adding a negative charge to T196 and S269,
blocked potentiation by UTP, but the alanine mutants (T196A
and S269A) were still enhanced by UTP, which renders the
174 D.A. Brown, D.I. Yule / Biochimica et Biophysica Acta 1773 (2007) 166–175importance of these PKC sites unclear [8]. Regardless, the
substrate of the putative ecto-protein kinase is not resolved; in
particular, it remains to be determined whether phosphoryla-
tion occurs at extracellular receptor sites or an accessory
membrane protein(s) [8].
The present study reports a previously unreported finding;
namely that PKC-mediated enhancement of P2X3R channel
activity does not seem to involve direct channel phosphoryla-
tion. These results suggest that the PMA-induced potentiation
of P2X3R signaling involves an unknown accessory protein.
In support of this contention, we also have shown that two
other P2XR family members, which also possess N-terminal
PKC sites, are not regulated by PKC activation, suggesting
these N-terminal PKC sites are not important for PKC-
mediated regulation. While it is possible that PKC-mediated
phosphorylation of P2X3R or P2X3R-EGFP was below the
level of detection in both our intact cell and in vitro systems,
this seems unlikely as the InsP3R type I and 3HA-M3R,
included as a positive controls were phosphorylated after
phorbol ester treatment or after incubation with active PKC
catalytic subunits as previously reported [28,29,31]. Further-
more, P2X1R are positively modulated by PKC activation,
however, it does not involve direct phosphorylation of the
receptor [31]. It is interesting to note that these two P2X
receptors belong to the same sub-group of P2XR based on
their rapid desensitization properties and high sensitivity to
ATP and selective agonist α, β-methylene ATP [3,35]. In
support of our findings, Vial and Evans were unable to
successfully measure phosphorylation of the P2X3R. How-
ever, in this case they attributed this finding to insufficient
expression levels of P2X3R achieved in HEK-293 cells in
their experiments [7]. In our transiently overexpressing HEK-
293 cell culture system the expression of the human P2X3R
or P2X3R-EGFP was unlikely to be an issue, since the
receptor was readily detected by immunoblotting using either
a P2X3R- or GFP-specific antibody (Figs. 4A and 7C).
One other possibility explaining why PKC-mediated phosphor-
ylation was not detected could be that the number of PKC sites was
significantly different in the InsP3R type I and 3HA-M3R when
compared to the P2X3R-EGFP. After PKC-mediated phosphoryla-
tion followed by thermolysin digestion and two-dimensional
phosphopeptide analysis, the InsP3R type I has been shown to
produce one major phosphopeptide and two minor phosphopep-
tides [28], suggesting that the InsP3R type I has potentially 3
different PKC sites. The number and location of the active PKC
phosphorylation sites in the humanM3R has not beenwell defined,
however, the number of active PKC sites in human M1R has been
determined to be 2–3 [36]. This number of sites seem reasonable
for comparison to potential P2X3R-EGFP PKC-mediated phos-
phorylation. In addition both proteins are similar in size (Fig. 7C).
Furthermore, a search of the human 3HA-M3R protein shows it
contains 17 PKC consensus sequences compared to 9 PKC
consensus sequences in the human P2X3R-EGFP using the search
criteria of [ST]X[RK] and including all regions of the receptor. If
the assumption is made that the stoichiometry of phosphorylation is
similar, one would expect to measure approximately half the
amount of phosphorylation in the P2X3R-EGFP compared to the3HA-M3R. Thus, it is reasonable to suggest, that since we can
robustly detect 3HA-M3R phosphorylation (Fig. 7A and B), that
P2X3R-EGFP phosphorylation should also be evident.
There is an emerging notion that P2XR activities are
modulated by a range of protein kinases [17,37]. Furthermore,
it appears that protein kinases can selectively modulate signaling
through different P2XR. Recent studies from our laboratory
have revealed that mechanisms that increase cellular adenosine
3′,5′-cyclic monophosphate (cAMP), activating PKA, can
significantly enhance both the Ca2+ signal and the cation current
through P2X4R, however, raising cAMP has no effect on P2X7R
signaling [17]. It remains to be determined if this regulation
involves direct receptor phosphorylation or not. Additionally,
P2X2R have also been shown to be regulated by PKA [37].
Given the preponderance of evidence, our results pose a novel
and interesting question, what is the identity of the unknown
accessory protein that modulates P2X3R? It is intriguing that this
protein is conserved in at least two different cell lines of chicken and
human origin (DT-40 and HEK-293) and future studies should be
directed to ascertain the identity of this seemingly ubiquitous
accessory protein and also to address whether it can associate and
regulate other P2XR. The current study helps support the notion
that accessory proteins play a significant role in both the regulation
andmodulation of P2XR. In support of this contention, a heat shock
protein, HSP90, was recently shown to interact with the P2X7R and
modulate the receptor when phosphorylated [38].
In summary, PKC modulation of P2X3R represents a mechan-
ism resulting in augmented intracellular Ca2+ signaling. These
results support the emerging consensus that protein kinases can
regulate P2XR signaling and therefore represent a point of
convergence between individual signaling systems. However,
importantly, it does not appear that the P2X3R is subject to a direct
PKC-mediated phosphorylation event. This is nevertheless likely
an important mechanism for selectively modulating P2XR and has
broad implications for the fidelity of downstream P2XR signaling.
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